Study on serum biomarkers in neonatal encephalopathy

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K17335
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 52050:Embryonic medicine and pediatrics-related
• Research Institution: Yamaguchi University
• Principal Investigator: Takahashi Kazumasa 山口大学, 医学部附属病院, 講師 (50526895)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 新生児脳症 / バイオマーカー / スペクトリン分解産物 / ST2

Outline of Final Research Achievements

We measured serum biomarkers in neonatal encephalopathy (NE) and examined their association with prognosis. serum SBDP120, serum SBDP145, and serum ST2 were measured in neonatal encephalopathy (mild NE, moderate NE, or severe NE) using residual serum within 6 hours after birth, at day 3, and at day 7. The SBDP120 and SBDP145 did not differ between the groups at any of the time phases and were not considered to be useful for predicting severity or prognosis in NE. On the other hand, ST2 values at ages 1 and 2 were higher in infants with cerebral palsy than in those without cerebral palsy, suggesting that ST2 may be useful as a marker to determine the severity of NE.

Free Research Field

小児科学

Academic Significance and Societal Importance of the Research Achievements

新生児脳症(NE)の重症度はSarnatやThompsonの分類により判定するが、主観的な要素が多く判断が難しい。また、NE予後を判断するバイオマーカーはあまり知られていない。日齢1の血清ST2値測定により、NE重症度と神経学的予後が客観的に判断されれば、より個々の症例にふさわしい治療法の選択が可能となるものと考えられる。